sever toxic secondari dehydrogenas defici common pharmacogenet syndrom studi inherit defect pyrimidin catabol associ drug-induc toxic patient fura adjuv chemotherapi breast carcinoma studi popul affect patient proband blood rel healthi volunt activ dihydropyrimidin dehydrogenas dpd initi enzym pyrimidin fura catabol peripher blood mononuclear cell subject specif radiometr assay fura substrat proband detect dpd activ enzym level proband rel control autosom recess pattern inherit third patient sever fura toxic secondari alter pyrimidin catabol second clinic popul frequenc genet defect dpd activ import manag patient sever toxic secondari fura chemotherapi 